UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The New England journal of medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1782 - 1791
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Immunopathology | General aspects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Bone marrow, stem cells transplantation. Graft versus host reaction | Transfusions. Complications. Transfusion reactions. Cell and gene therapy | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Thalidomide - adverse effects | Double-Blind Method | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Neoplasms, Second Primary - epidemiology | Stem Cell Transplantation | Young Adult | Disease-Free Survival | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Thalidomide - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Usage | Multiple myeloma | Stem cells | Product/Service Evaluations | Transplantation | Drug therapy | Autografts | Chemotherapy | Consolidation | Transplants & implants | Clinical trials | Stem cell transplantation | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Abridged Index Medicus | Antineoplastic Agents | Life Sciences | Neoplasms, Second Primary | Thalidomide | Multiple Myeloma | Cancer
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3279 - 3289
Life Sciences & Biomedicine | Oncology | Science & Technology | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Transplantation, Autologous | Young Adult | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - administration & dosage | Multiple Myeloma - therapy | Time Factors | Adult | Female | Maintenance Chemotherapy | Chemotherapy, Adjuvant | Stem Cell Transplantation - mortality | Angiogenesis Inhibitors - adverse effects | Thalidomide - adverse effects | Drug Administration Schedule | Lenalidomide | Multiple Myeloma - diagnosis | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Thalidomide - administration & dosage | Disease Progression | Randomized Controlled Trials as Topic | Disease-Free Survival | Aged | Stem Cell Transplantation - adverse effects | Index Medicus | Life Sciences | Angiogenesis Inhibitors/administration & dosage | Multiple Myeloma/therapy | Thalidomide/analogs & derivatives | Cancer | Rapid Communications | Myeloma | Clinical Trials | ORIGINAL REPORTS
Journal Article
Cellular signalling, ISSN 0898-6568, 09/2014, Volume 26, Issue 9, pp. 2016 - 2029
Phosphodiesterase inhibitor | Apremilast | Spondyloarthropathies | Psoriasis | Preclinical drug evaluation | Psoriatic arthritis | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Thalidomide - metabolism | Humans | Male | Thalidomide - pharmacology | Lung Diseases - drug therapy | Thalidomide - analogs & derivatives | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Female | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Vomiting - prevention & control | B-Lymphocytes - metabolism | Disease Models, Animal | Cell Line | Cytokines - metabolism | Immunity, Innate - drug effects | Jurkat Cells | Phosphodiesterase 4 Inhibitors - therapeutic use | Mice, Transgenic | Phosphodiesterase 4 Inhibitors - metabolism | Ferrets | Phosphodiesterase 4 Inhibitors - pharmacology | B-Lymphocytes - drug effects | Adaptive Immunity - drug effects | Animals | B-Lymphocytes - immunology | Protein Binding | T-Lymphocytes - immunology | Mice | Thalidomide - therapeutic use | Dendritic cells | Analysis | Development and progression | Genetic engineering | B cells | Biological response modifiers | T cells | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2018, Volume 379, Issue 10, pp. 934 - 947
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thalidomide - adverse effects | Skin Diseases - chemically induced | Lymphoma, Follicular - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lymphoma, Follicular - mortality | Male | Survival Rate | Thalidomide - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Thalidomide - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Neutropenia - chemically induced | Rituximab - adverse effects | Chemotherapy | Usage | Lymphomas | Drug therapy | Cancer | Fees & charges | Lymphocytes B | Immunomodulation | Immunotherapy | Advisors | Rituximab | Clinical medicine | Patients | Lymphoma | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus | Life Sciences
Journal Article
Bioorganic & medicinal chemistry, ISSN 0968-0896, 07/2009, Volume 17, Issue 14
Journal Article
The New England journal of medicine, ISSN 0028-4793, 09/2010, Volume 363, Issue 11, pp. 1025 - 1037
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | ADP-ribosyl Cyclase 1 - analysis | Antigens, CD34 - analysis | Neoplastic Stem Cells - drug effects | Humans | Middle Aged | Neoplastic Stem Cells - immunology | Male | Antineoplastic Agents - therapeutic use | Thalidomide - pharmacology | Thalidomide - analogs & derivatives | Aged, 80 and over | Female | Antineoplastic Agents - pharmacology | Myelodysplastic Syndromes - drug therapy | Chromosomes, Human, Pair 5 - genetics | Chromosome Deletion | Gene Expression | Remission Induction | Drug Resistance - genetics | Phenotype | Aged | Myelodysplastic Syndromes - genetics | Thalidomide - therapeutic use | Myelodysplastic Syndromes - pathology | Thy-1 Antigens - analysis | Stem cells | Physiological aspects | Chromosome deletion | Genetic aspects | Diagnosis | Research | Health aspects | Myelodysplastic syndromes | Bone marrow | Patients | Cancer | Index Medicus | Abridged Index Medicus | Thalidomide: therapeutic use | Myelodysplastic Syndromes: pathology | Neoplastic Stem Cells: drug effects | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinsk genetik | Medical Genetics | Antineoplastic Agents: pharmacology | Thalidomide: analogs & derivatives | Myelodysplastic Syndromes: genetics | CD34: analysis | Chromosomes | Pair 5: genetics | Human | Antigens | Basic Medicine | Thy-1: analysis | Cell and Molecular Biology | Drug Resistance: genetics | CD38: analysis | Thalidomide: pharmacology | Neoplastic Stem Cells: immunology | Medicinska och farmaceutiska grundvetenskaper | Antineoplastic Agents: therapeutic use | Myelodysplastic Syndromes: drug therapy | Cell- och molekylärbiologi
Journal Article
Nature structural & molecular biology, ISSN 1545-9993, 09/2014, Volume 21, Issue 9, pp. 803 - 809
Biochemistry & Molecular Biology | Biophysics | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Protein Structure, Tertiary | Amino Acid Sequence | Lenalidomide | Humans | Thalidomide - chemistry | Angiogenesis Inhibitors - pharmacology | Molecular Sequence Data | Crystallography, X-Ray | Thalidomide - pharmacology | DNA-Binding Proteins - chemistry | Peptide Hydrolases - chemistry | DNA-Binding Proteins - metabolism | Thalidomide - analogs & derivatives | Sequence Alignment | Animals | Protein Binding | Protein Conformation | Mice | Molecular Docking Simulation | Angiogenesis Inhibitors - chemistry | Peptide Hydrolases - metabolism | Research | Structure | Thalidomide | Patient outcomes | Crystals | Proteins | Cancer therapies | Pharmacology | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences | Cancer
Journal Article